NASDAQ$PHVS
Pharvaris NV · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Pharvaris Q4 2024: €34.8M net loss, €0.64 loss per share as Phase 3 HAE programs advance
Pharvaris reported fourth quarter and full year 2024 financial results alongside a pipeline update for deucrictibant, its oral bradykinin B2 receptor antagonist for hereditary angioedema. The company recorded a Q4 2024 loss of €34.8 million, or €0.64 per basic and diluted share, compared with a €32.7 million loss (€0.95 per share) in Q4 2023. For the full year, the loss widened to €134.2 million, or €2.48 per share, from €100.9 million (€2.63 per share) in 2023. R&D spending rose to €31.2 million in Q4 and €98.6 million for the year, reflecting accelerated Phase 3 enrollment in RAPIDe-3 and CHAPTER-3. Cash and cash equivalents stood at €281 million at December 31, 2024, down from €391 million a year earlier. Management highlighted target enrollment in the pivotal on-demand RAPIDe-3 study, ongoing enrollment in prophylaxis study CHAPTER-3 with topline data expected in the second half of 2026, and European orphan medicinal product designation granted in March 2025.
- Q4 2024 net loss was €34.8 million (€0.64 per share) versus €32.7 million (€0.95 per share) in Q4 2023; full-year 2024 loss totaled €134.2 million (€2.48 per share).
- R&D expenses increased to €31.2 million in Q4 and €98.6 million for FY2024, up from €18.6 million and €65.6 million respectively in the prior year, driven by Phase 3 trial activity.
- Cash and cash equivalents were €281 million at December 31, 2024, compared with €391 million at year-end 2023.
- RAPIDe-3 reached target enrollment for on-demand HAE treatment; CHAPTER-3 prophylaxis enrollment is progressing with topline data expected in 2H2026.
- European Commission granted orphan medicinal product designation to deucrictibant for bradykinin-mediated angioedema in March 2025.
Headline financials
Revenue & EPS history
Pharvaris · Revenue · Quarterly
€0
Forward guidance
Pharvaris expects topline data from the CHAPTER-3 prophylaxis Phase 3 study in the second half of 2026; RAPIDe-3 on-demand enrollment target has been achieved.
Tailwinds
- RAPIDe-3 pivotal on-demand study reached target enrollment
- CHAPTER-3 prophylaxis enrollment progressing on plan
Headwinds
- Continued operating losses and cash burn as clinical programs scale
- Topline CHAPTER-3 data not expected until 2H2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q4 2024
+16.7%
Avg return
Earnings day
+16.1%
Avg return
5 days after
+27.4%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+243.4%
Q3 2022
Best reaction
-10.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | +1.5% | +7.3% | |
| Q3 2025 | +7.3% | +3.3% | +0.2% | |
| Q4 2024 | -10.4% | -9.2% | +29.0% | |
| Q3 2024 | +3.6% | +5.4% | -7.3% | |
| Q4 2023 | -3.6% | -12.9% | -7.3% | |
| Q3 2023 | +9.3% | +2.7% | +9.9% | |
| Q2 2023 | -3.9% | -1.4% | +11.6% | |
| Q4 2022 | -5.2% | -2.0% | +9.0% | |
| Q3 2022 | +243.4% | +241.4% | +376.1% | |
| Q2 2022 | -2.7% | -2.1% | -46.3% | |
| Q4 2021 | -0.8% | -0.4% | -1.1% | |
| Q3 2021 | -0.2% | -0.8% | -6.8% | |
| Q2 2021 | -2.4% | -1.8% | +18.0% | |
| Q1 2021 | +0.0% | +1.2% | -8.7% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro